Matches in SemOpenAlex for { <https://semopenalex.org/work/W4290964372> ?p ?o ?g. }
- W4290964372 endingPage "104219" @default.
- W4290964372 startingPage "104219" @default.
- W4290964372 abstract "Cancer is replacing cardiovascular-disease as a leading cause of death in type 2 diabetes (T2D). The association of RAS-inhibitors (RASi) and cancer, including differences between angiotensin-converting-enzyme-inhibitor (ACEi) and angiotensin-receptor-blocker (ARBs) as well as their associations independent of blood pressure lowering, remains inconclusive in T2D.We conducted a cohort study with new-user design in 253,491 patients in the Hong-Kong-Diabetes-Surveillance-Database (HKDSD) in 2002-2019. We evaluated the associations of time-varying RASi use (ACEi and ARBs) with all-site cancer, diabetes-related cancers, and cancer-specific mortality including comparison with new-users of calcium-channel-blockers (CCBs) as an active-comparator group.Of 253,491, 133,730 (52.8%) were new-RASi and 119,761 (47.2%) were non-RASi users with a median follow-up period of 6.3 (interquartile ragne: 3.4-9.2) years (1,678,719 patient-years). After propensity-score weighting and adjustment for time-varying covariables, RASi use was associated with lower risk of all-site cancer (HR=0.76, 95%CI: 0.74-0.79), diabetes-related cancer (HR=0.79, 95%CI: 0.75-0.84), cancer-specific mortality (HR=0.50, 95%CI: 0.47-0.53), and diabetes-related cancer mortality (HR=0.49, 95%CI: 0.45-0.54) versus non-RASi. Amongst RASi users, ARBs use was associated with lower risk of cancer-specific mortality versus ACEi (HR=0.77, 95%CI: 0.66-0.91). Use of RASi was associated with an estimated-prevention of 2.6 (95%CI: 2.3-3.0) all-site cancer per-1000-person-years and 2.2 (95%CI: 2.0-2.5) cancer-related mortality per-1000-person-years. Lower risk of cancer-specific mortality was similarly observed in new-RASi compared with new-CCBs users.RASi use was independently associated with lower cancer risk in T2D with stronger associations in users of ARBs than ACEi. The benefits of RASi in patients with diabetes might go beyond cardiovascular-renal protection if confirmed by other real-world studies and trials.Dr. Aimin Yang was supported by a CUHK Impact-Research-Fellowship Scheme." @default.
- W4290964372 created "2022-08-13" @default.
- W4290964372 creator A5007921065 @default.
- W4290964372 creator A5017001136 @default.
- W4290964372 creator A5020273125 @default.
- W4290964372 creator A5022472943 @default.
- W4290964372 creator A5023590941 @default.
- W4290964372 creator A5027757155 @default.
- W4290964372 creator A5037855971 @default.
- W4290964372 creator A5040544030 @default.
- W4290964372 creator A5072979521 @default.
- W4290964372 creator A5086738346 @default.
- W4290964372 date "2022-09-01" @default.
- W4290964372 modified "2023-09-30" @default.
- W4290964372 title "Effects of RAS inhibitors on all-site cancers and mortality in the Hong Kong diabetes surveillance database (2002-2019)" @default.
- W4290964372 cites W108690756 @default.
- W4290964372 cites W1568390176 @default.
- W4290964372 cites W1569124499 @default.
- W4290964372 cites W1600041372 @default.
- W4290964372 cites W1618055289 @default.
- W4290964372 cites W1989699585 @default.
- W4290964372 cites W1990719139 @default.
- W4290964372 cites W1996913485 @default.
- W4290964372 cites W2008114169 @default.
- W4290964372 cites W2038118918 @default.
- W4290964372 cites W2043750081 @default.
- W4290964372 cites W2052329642 @default.
- W4290964372 cites W2072952421 @default.
- W4290964372 cites W2094546405 @default.
- W4290964372 cites W2104195235 @default.
- W4290964372 cites W2105473163 @default.
- W4290964372 cites W2119562899 @default.
- W4290964372 cites W2126919962 @default.
- W4290964372 cites W2140319788 @default.
- W4290964372 cites W2142080475 @default.
- W4290964372 cites W2143756124 @default.
- W4290964372 cites W2165345246 @default.
- W4290964372 cites W2554614845 @default.
- W4290964372 cites W2764256970 @default.
- W4290964372 cites W2779763511 @default.
- W4290964372 cites W2782899595 @default.
- W4290964372 cites W2791911538 @default.
- W4290964372 cites W2903401658 @default.
- W4290964372 cites W2953323316 @default.
- W4290964372 cites W2955819261 @default.
- W4290964372 cites W2974039187 @default.
- W4290964372 cites W2985331915 @default.
- W4290964372 cites W2999081419 @default.
- W4290964372 cites W3011104356 @default.
- W4290964372 cites W3016046665 @default.
- W4290964372 cites W3023814660 @default.
- W4290964372 cites W3029472550 @default.
- W4290964372 cites W3043523396 @default.
- W4290964372 cites W3092470915 @default.
- W4290964372 cites W3110110218 @default.
- W4290964372 cites W3127351741 @default.
- W4290964372 cites W3128646645 @default.
- W4290964372 cites W3134769649 @default.
- W4290964372 cites W3145416765 @default.
- W4290964372 cites W3165720345 @default.
- W4290964372 cites W4200028200 @default.
- W4290964372 cites W4200130376 @default.
- W4290964372 cites W4205256538 @default.
- W4290964372 cites W4210495025 @default.
- W4290964372 cites W4225939851 @default.
- W4290964372 doi "https://doi.org/10.1016/j.ebiom.2022.104219" @default.
- W4290964372 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35970023" @default.
- W4290964372 hasPublicationYear "2022" @default.
- W4290964372 type Work @default.
- W4290964372 citedByCount "4" @default.
- W4290964372 countsByYear W42909643722023 @default.
- W4290964372 crossrefType "journal-article" @default.
- W4290964372 hasAuthorship W4290964372A5007921065 @default.
- W4290964372 hasAuthorship W4290964372A5017001136 @default.
- W4290964372 hasAuthorship W4290964372A5020273125 @default.
- W4290964372 hasAuthorship W4290964372A5022472943 @default.
- W4290964372 hasAuthorship W4290964372A5023590941 @default.
- W4290964372 hasAuthorship W4290964372A5027757155 @default.
- W4290964372 hasAuthorship W4290964372A5037855971 @default.
- W4290964372 hasAuthorship W4290964372A5040544030 @default.
- W4290964372 hasAuthorship W4290964372A5072979521 @default.
- W4290964372 hasAuthorship W4290964372A5086738346 @default.
- W4290964372 hasBestOaLocation W42909643723 @default.
- W4290964372 hasConcept C119060515 @default.
- W4290964372 hasConcept C121608353 @default.
- W4290964372 hasConcept C126322002 @default.
- W4290964372 hasConcept C134018914 @default.
- W4290964372 hasConcept C143998085 @default.
- W4290964372 hasConcept C2777180221 @default.
- W4290964372 hasConcept C2778527826 @default.
- W4290964372 hasConcept C555293320 @default.
- W4290964372 hasConcept C71924100 @default.
- W4290964372 hasConcept C72563966 @default.
- W4290964372 hasConceptScore W4290964372C119060515 @default.
- W4290964372 hasConceptScore W4290964372C121608353 @default.
- W4290964372 hasConceptScore W4290964372C126322002 @default.
- W4290964372 hasConceptScore W4290964372C134018914 @default.
- W4290964372 hasConceptScore W4290964372C143998085 @default.